Traws Pharma’s (TRAW) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Traws Pharma (NASDAQ:TRAW) in a research report released on Tuesday morning, MarketBeat.com reports. HC Wainwright currently has a $1.00 target price on the stock. HC Wainwright also issued estimates for Traws Pharma’s Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.60) EPS, FY2029 earnings at ($0.34) EPS and FY2030 earnings at $0.02 EPS.

A number of other research firms also recently issued reports on TRAW. Citigroup downgraded Traws Pharma to a “neutral” rating in a research note on Monday, June 15th. Wall Street Zen upgraded Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Weiss Ratings cut Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. Finally, LADENBURG THALM/SH SH cut Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $1.00.

Traws Pharma Price Performance

Shares of NASDAQ TRAW opened at $0.52 on Tuesday. The stock has a market capitalization of $7.99 million, a P/E ratio of -0.30 and a beta of 1.57. The company has a 50-day moving average price of $0.67 and a 200-day moving average price of $1.31. Traws Pharma has a 1 year low of $0.43 and a 1 year high of $3.27.

Traws Pharma (NASDAQ:TRAW) last posted its earnings results on Friday, August 14th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. As a group, equities research analysts anticipate that Traws Pharma will post -1.2 earnings per share for the current fiscal year.

Institutional Trading of Traws Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Investments LP lifted its holdings in Traws Pharma by 37.1% during the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after acquiring an additional 5,955 shares during the period. Geode Capital Management LLC grew its stake in Traws Pharma by 41.9% in the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after purchasing an additional 18,213 shares during the period. State Street Corp purchased a new stake in shares of Traws Pharma during the 4th quarter valued at $29,000. Adage Capital Partners GP L.L.C. increased its position in shares of Traws Pharma by 121.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock valued at $825,000 after purchasing an additional 400,000 shares during the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Traws Pharma during the 4th quarter valued at $175,000. 7.95% of the stock is owned by hedge funds and other institutional investors.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.